Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Researchers at Cold Spring Harbor Laboratory have found that blocking the FGFR2 and EGFR genes can stop early-stage ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Patients with EGFR-positive non-small cell lung cancer (NSCLC) do not respond as well to immunotherapy as patients without an EGFR mutation. Nevertheless, recent studies indicate that subsequent ...

Circulating tumor cell (CTC) analysis is a promising minimally invasive biomarker for monitoring treatment response and stratifying prognosis in EGFR-mutant non-small cell lung cancer (NSCLC).

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

AACR's achievement awards and lectureships recognize innovation in basic, translational, clinical, and epidemiological cancer research.